Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome

Movement Disorders

Volumn 32, Issue 5, 2017, Pages 739-749

  Hill Burns, Erin M ^a   Debelius, Justine W ^b   Morton, James T ^c   Wissemann, William T ^a   Lewis, Matthew R ^a   Wallen, Zachary D ^a   Peddada, Shyamal D ^d   Factor, Stewart A ^e   Molho, Eric ^f   Zabetian, Cyrus P ^g   Knight, Rob ^b,c,h   Payami, Haydeh ^a,i  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f ALBANY MEDICAL COLLEGE   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

ⁱ HudsonAlpha Institute for Biotechnology   (United States)

Author keywords

confounding; functional pathways; gut microbiome; medications; Parkinson's disease

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; MONOAMINE OXIDASE INHIBITOR; XENOBIOTIC AGENT; CARBIDOPA; CARBIDOPA, LEVODOPA DRUG COMBINATION; LEVODOPA; RNA 16S;

AGE; ARTICLE; BIFIDOBACTERIACEAE; CASE CONTROL STUDY; CHRISTENSENELLACEAE; CONTROLLED STUDY; DIETARY INTAKE; DYSBIOSIS; FEMALE; FRUIT; HUMAN; INTESTINE FLORA; LACHNOSPIRACEAE; LACTOBACILLACEAE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PARKINSON DISEASE; PASTEURELLACEAE; PRIORITY JOURNAL; SEX; UNITED STATES; VEGETABLE; VERRUCOMICROBIACEAE; XENOBIOTIC METABOLISM; BIFIDOBACTERIUM; DIET; DRUG COMBINATION; EPIDEMIOLOGY; GENETICS; MICROBIOLOGY; RISK FACTOR; SEX FACTOR; VERRUCOMICROBIA;

AGE FACTORS; ANTIPARKINSON AGENTS; BIFIDOBACTERIUM; CARBIDOPA; CASE-CONTROL STUDIES; CATECHOL O-METHYLTRANSFERASE INHIBITORS; CHOLINERGIC ANTAGONISTS; CONFOUNDING FACTORS (EPIDEMIOLOGY); DIET; DRUG COMBINATIONS; DYSBIOSIS; FEMALE; FRUIT; GASTROINTESTINAL MICROBIOME; HUMANS; LACTOBACILLACEAE; LEVODOPA; MALE; PARKINSON DISEASE; PASTEURELLACEAE; RISK FACTORS; RNA, RIBOSOMAL, 16S; SEX FACTORS; UNITED STATES; VEGETABLES; VERRUCOMICROBIA;

EID: 85013158306     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26942     Document Type: Article

References (54)

1. Cersosimo MG, Raina GB, Pecci C, et al. Gastrointestinal manifestations in Parkinson's disease: prevalence and occurrence before motor symptoms. J Neurol 2013;260(5):1332–1338.
2. Adler CH, Beach TG. Neuropathological basis of nonmotor manifestations of Parkinson's disease. Mov Disord 2016;31(8):1114–1119.
3. Devos D, Lebouvier T, Lardeux B, et al. Colonic inflammation in Parkinson's disease. Neurobiol Dis 2013;50:42–48.
4. Forsyth CB, Shannon KM, Kordower JH, et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One 2011;6(12):e28032.
5. Svensson E, Horvath-Puho E, Thomsen RW, et al. Vagotomy and subsequent risk of Parkinson's disease. Ann Neurol 2015;78(4):522–529.
6. Falony G, Joossens M, Vieira-Silva S, et al. Population-level analysis of gut microbiome variation. Science 2016;352(6285):560–564.
7. Zhernakova A, Kurilshikov A, Bonder MJ, et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 2016;352(6285):565–569.
8. Arnold JW, Roach J, Azcarate-Peril MA. Emerging technologies for gut microbiome research. Trends Microbiol 2016;24(11):887–901.
9. Forslund K, Hildebrand F, Nielsen T, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 2015;528(7581):262–266.
10. Sampson TR, Debelius JW, Thron T, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell 2016;167(6):1469–1480.e12.
11. Scheperjans F, Aho V, Pereira PA, et al. Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord 2015;30(3):350–358.
12. Keshavarzian A, Green SJ, Engen PA, et al. Colonic bacterial composition in Parkinson's disease. Mov Disord 2015;30(10):1351–1360.
13. Hasegawa S, Goto S, Tsuji H, et al. Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson's disease. PLoS One 2015;10(11):e0142164.
14. Unger MM, Spiegel J, Dillmann KU, et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. Parkinsonism Relat Disord 2016;32:66–72.
15. Hamza TH, Zabetian CP, Tenesa A, et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet 2010;42(9):781–785.
16. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–184.
17. Caporaso JG, Lauber CL, Walters WA, et al. Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. ISME J 2012;6(8):1621–1624.
18. Caporaso JG, Lauber CL, Walters WA, et al. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. Proc Natl Acad Sci U S A 2011;108(suppl 1):4516–4522.
19. Kuczynski J, Stombaugh J, Walters WA, Gonzalez A, Caporaso JG, Knight R. Using QIIME to analyze 16S rRNA gene sequences from microbial communities. Curr Protoc Bioinformatics 2011;chapter 10:unit 10.17.
20. Kopylova E, Noe L, Touzet H. SortMeRNA: fast and accurate filtering of ribosomal RNAs in metatranscriptomic data. Bioinformatics 2012;28(24):3211–3217.
21. McDonald D, Price MN, Goodrich J, et al. An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. ISME J 2012;6(3):610–618.
22. Ritari J, Salojarvi J, Lahti L, de Vos WM. Improved taxonomic assignment of human intestinal 16S rRNA sequences by a dedicated reference database. BMC Genomics 2015;16:1056.
23. Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol 2007;73(16):5261–5267.
24. Lozupone C, Knight R. UniFrac: a new phylogenetic method for comparing microbial communities. Appl Environ Microbiol 2005;71(12):8228–8235.
25. Lance GN, Williams WT. Computer programs for hierarchical polythetic classification (“similarity analyses”). Comput J 1966;9(1):60–64.
26. Cao Y, Williams WP, Bark AW. Similarity measure bias in river benthic Aufwuchs community analysis. Water Environ Res 1997;69(1):95–106.
27. Anderson MJ. A new method for non-parametric multivariate analysis of variance. Austral Ecol 2001;26(1):32–46.
28. Mandal S, Van Treuren W, White RA, Eggesbo M, Knight R, Peddada SD. Analysis of composition of microbiomes: a novel method for studying microbial composition. Microb Ecol Health Dis 2015;26:27663.
29. Hollander M, Wolfe DA. Nonparametric Statistical Methods. New York: John Wiley & Sons, 1973.
30. Langille MG, Zaneveld J, Caporaso JG, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol 2013;31(9):814–821.
31. Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M. The KEGG resource for deciphering the genome. Nucleic Acids Res 2004;32(Database issue):D277–D280.
32. Parks DH, Tyson GW, Hugenholtz P, Beiko RG. STAMP: statistical analysis of taxonomic and functional profiles. Bioinformatics 2014;30(21):3123–3124.
33. Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 2000;59(6):1233–1250.
34. Ness J, Hoth A, Barnett MJ, Shorr RI, Kaboli PJ. Anticholinergic medications in community-dwelling older veterans: prevalence of anticholinergic symptoms, symptom burden, and adverse drug events. Am J Geriatr Pharmacother 2006;4(1):42–51.
35. Kidd SK, Schneider JS. Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition. Brain Res 2010;1354:172–178.
36. St Laurent R, O'Brien LM, Ahmad ST. Sodium butyrate improves locomotor impairment and early mortality in a rotenone-induced Drosophila model of Parkinson's disease. Neuroscience 2013;246:382–390.
37. Sharma S, Taliyan R, Singh S. Beneficial effects of sodium butyrate in 6-OHDA induced neurotoxicity and behavioral abnormalities: Modulation of histone deacetylase activity. Behav Brain Res 2015;291:306–314.
38. Louis P, Duncan SH, McCrae SI, Millar J, Jackson MS, Flint HJ. Restricted distribution of the butyrate kinase pathway among butyrate-producing bacteria from the human colon. J Bacteriol 2004;186(7):2099–2106.
39. Kumari S, Tishel R, Eisenbach M, Wolfe AJ. Cloning, characterization, and functional expression of acs, the gene which encodes acetyl coenzyme A synthetase in Escherichia coli. J Bacteriol 1995;177(10):2878–2886.
40. Erny D, Hrabe de Angelis AL, Jaitin D, et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci 2015;18(7):965–977.
41. Sanchez-Guajardo V, Tentillier N, Romero-Ramos M. The relation between alpha-synuclein and microglia in Parkinson's disease: recent developments. Neuroscience 2015;302:47–58.
42. Donohoe DR, Garge N, Zhang X, et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab 2011;13(5):517–526.
43. Pituch A, Walkowiak J, Banaszkiewicz A. Butyric acid in functional constipation. Prz Gastroenterol 2013;8(5):295–298.
44. Segain JP, Raingeard de la Bletiere D, Bourreille A, et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 2000;47(3):397–403.
45. Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013;504(7480):446–450.
46. Pozuelo M, Panda S, Santiago A, et al. Reduction of butyrate- and methane-producing microorganisms in patients with irritable bowel syndrome. Sci Rep 2015;5:12693.
47. Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012;490(7418):55–60.
48. Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 2014;513(7516):59–64.
49. Guo Z, Zhang J, Wang Z, et al. Intestinal microbiota distinguish gout patients from healthy humans. Sci Rep 2016;6:20602.
50. Yamada T, Shimizu K, Ogura H, et al. Rapid and Sustained long-term decrease of fecal short-chain fatty acids in critically ill patients with systemic inflammatory response syndrome. J Parenter Enteral Nutr 2015;39(5):569–577.
51. Gatto NM, Cockburn M, Bronstein J, Manthripragada AD, Ritz B. Well-water consumption and Parkinson's disease in rural California. Environ Health Perspect 2009;117(12):1912–1918.
52. Freire C, Koifman S. Pesticide exposure and Parkinson's disease: epidemiological evidence of association. Neurotoxicology 2012;33(5):947–971.
53. Blesa J, Phani S, Jackson-Lewis V, Przedborski S. Classic and new animal models of Parkinson's disease. J Biomed Biotechnol 2012;2012:845618.
54. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature 2011;473(7346):174–180.